Economic burden of non-cervical cancers attributable to human papillomavirus: A European scoping review

Journal of Medical Economics

Volumn 16, Issue 6, 2013, Pages 763-776

  Préaud, Emmanuelle ^a   Largeron, Nathalie ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Cost of illness; Economic burden; Europe; Human papillomavirus; Human papillomavirus related cancers

Indexed keywords

ANUS CANCER; ATTRIBUTABLE RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DENMARK; FRANCE; GERMANY; GREECE; HEAD AND NECK CANCER; HOSPITALIZATION COST; HUMAN; MULTIPLE CANCER; NEOPLASM; NETHERLANDS; NON CERVICAL CANCER; PENIS CANCER; PORTUGAL; REVIEW; SYSTEMATIC REVIEW; UNITED KINGDOM; VAGINA CANCER; VULVA CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; CONDYLOMATA ACUMINATA; COST OF ILLNESS; EUROPE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 84878918620     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.793691     Document Type: Review

References (71)

1. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603
2. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24(3 Suppl):S3/11-25
3. Wallboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19
4. Aubin F, Pré tet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008;47:610-5
5. Donne AJ, Hampson L, Homer JJ, et al. The role of HPV type in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2010;74:7-14
6. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626-36
7. Gillison M. HPV and its effect on head and neck cancer prognosis. Clin Adv Hematol Oncol 2010;8:680-2
8. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26(10 Suppl):K17-28
9. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27
10. Kirrander P, Kolaric A, Helenius G, et al. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int 2011;108:355-9
11. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32
12. Acay R, Rezende N, Fontes A, et al. Human papillomavirus as a risk factor in oral carcinogenesis: a study using in situ hybridization with signal amplification. Oral Microbiol Immunol 2008;23:271-4
13. Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol 2012;5:25-36
14. Sanchez GI, Jaramillo R, Cuello G, et al. Human papillomavirus genotype detection in recurrent respiratory papillomatosis (RRP) in Colombia. Head Neck 2013;35:229-34
15. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
16. Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86
17. Ting J, Kruzikas DT, Smith JS. A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer 2010;20:1244-9
18. Arveux P, Bé nard S, Boué e S, et al. [Invasive cervical cancer treatment costs in France]. Bull Cancer 2007;94:219-24 [Article in French]
19. Ricciardi A, Largeron N, Giorgi Rossi P, et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori 2009;95:146-52
20. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70
21. Robinson D, Coupland V, Møller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009;100:527-31
22. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and highgrade anal intraepithelial neoplasia in Denmark, 1978-2008
23. Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 2011;31:1515-9
24. Attner P, Du J, Näsman A, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010;126: 2879-84
25. Mehanna H, Jones TM, Gregoire V, et al. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439
26. Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012;12:30
27. Karnon J, Jones R, Czoski-Murray C, et al. Cost-utility analysis of screening high-risk groups for anal cancer. J Public Health 2008;30:293-304
28. Czoski-Murray C, Karnon J, Jones R, et al. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010;14:1-131
29. Abramowitz L, Rémy V, Vainchtock A. Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique 2010;58:331-8
30. Rémy V, Vainchtock A. Hospitalisation and management costs of patients with penile cancer in France. Paris, France: European Academy of Dermatology and Venereology (EADV), 2008 [Poster presentation]
31. Rémy V, Mathevet P, Largeron N, et al. Cost of management of vulvar and vaginal cancers in France. Journal d'Economie Mé dicale 2010;28:31-45
32. Mignogna MD, Fedele S, Lo Russo L, et al. Costs and effectiveness in the care of patients with oral and pharyngeal cancer: analysis of a paradox. Eur J Cancer Prev 2002;11:205-8
33. Speight PM, Palmer S, Moles DR, et al. The cost-effectiveness of screening for oral cancer in primary care. Health Technol Assess 2006;10:1-144
34. Kim K, Amonkar MM, Högberg D, et al. Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol 2011;3:1-10
35. Selke B, Allenet B, Bercez C, et al. [Economic assessments of head and neck cancers: a review]. Bull Cancer 2001;88:759-64 [Article in French]
36. Kim K, Faivre P, Cancalon C, et al. Healthcare utilisation and costs of resected squamous cell carcinoma of head and neck (SCCHN) in France. Barcelona, Spain: European Society for Therapeutic Radiology and Oncology (ESTRO), 2010 [Poster presentation]
37. Lacau St Guily JL, Borget I, Vainchtock A, et al. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol 2010;2:22
38. Ruff LK, Volmer T, Nowak D, et al. The economic impact of smoking in Germany. Eur Respir J 2000;16:385-90
39. van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001;37:2204-11
40. Nijdam W, Levendag P, Noever I, et al. Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol 2005;77:65-72
41. van Agthoven M, Heule-Dieleman HAG, Knegt PP, et al. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol 2006;263:729-37
42. Zavras A, Andreopoulos N, Katsikeris N, et al. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002;2:12
43. Olsen J. Incidence and costs of anal, penile, vaginal, vulva and head and neck cancer in Denmark. Lisbon, Portugal: European Research Organisation on Genital Infection and Neoplasia (EUROGIN), 2011 [Oral presentation]
44. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:d5775
45. Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine 2011;29:5245-9
46. Rémy V, Heitland W, Klussmann J, et al. Economic burden of HPV-related head & neck and anal cancers in Germany. Value Health 2011;14:A443
47. Santana R, Lopes S, Costa C. Human papillomavirus disease burden in Portugal. Lisbon, Portugal: European Research Organisation on Genital Infection and Neoplasia (EUROGIN), 2011 [Poster presentation]
48. Bongers V, Hobbelink MG, van Rijk PP, et al. Cost-effectiveness of dual-head 18F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer. Cancer Biother Radiopharm 2002;17:303-6
49. Baujat B, Altabaa K, Meyers M, et al. Medicoeconomic study of microsurgical head and neck reconstructions. Eur Ann Otorhinolaryngol Head Neck Dis 2011;128:121-6
50. Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 2004;40:372-82
51. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland and the United Kingdom. Value Health 2008;11:791-9
52. Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol 2005;44:850-61
53. Bonastre MJ, Noë l E, Bensadoun RJ, et al. The cost of intensity modulated radiation therapy in head and neck cancers: results of the 2002 STIC study. Bull Cancer 2006;93:1026-32
54. Nijdam W, Levendag P, Noever I, et al. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys 2004;59:488-94
55. Leon X, Quer M, Orus C, et al. How much does it cost to preserve a larynx? An economic study. Eur Arch Otorhinolaryngol 2000;257:72-6
56. Watters K, O'Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol 2004;118:694-9
57. Penel N, Lefebvre JL, Cazin JL, et al. Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. Int J Oral Maxillofac Surg 2008;37:135-9
58. Bennett CL, Lane D, Stinson T, et al. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 2001;19:107-13
59. Preuss SF, Quante G, Semrau R, et al. An analysis of surgical complications, morbidity, and cost calculation in patients undergoing multimodal treatment for operable oropharyngeal carcinoma. Laryngoscope 2007;117:101-5
60. Braaksma M, van Agthoven AM, Nijdam W, et al. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomized for radioprotection with amifostine. Eur J Cancer 2005;41:2102-11
61. Hampl M, Huppertz E, Schulz-Holstege O, et al. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre. BMC Infect Dis 2011;11:73
62. Olsen J, Jørgensen TR, Kofoed K, et al. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health 2012;12:1082
63. Heitland W, Schädlich PK, Chen X, et al. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. J Med Econom 2013;16:364-71
64. Klussmann JP, Schädlich PK, Chen X, et al. Annual cost of hospitalization, inpatient rehabilitation, and sick leave of head and neck cancers in Germany. ClinicoEconom Outcomes Res 2013; accepted for publication
65. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81
66. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008;11:791-9
67. Hu D, Goldie SJ. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500-7
68. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9
69. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9
70. Szucs TD, Dedes KJ. Balancing costs and benefits in cancer therapy and prevention. Ann Oncol 2008;19(7 Suppl):vii313-9
71. Olsen J, Jorgensen TR, Rubek N. The economic burden of head and neck cancers in Denmark. Int J Otolaryngol Head Neck Cancers 2013; accepted for publication